🔥 Presidential Symposium I #ESMO26

🗣️ @tompowles1

👉🏽 VOLGA phase 3, randomised, open-label trial, enrolled pts with MIBC (cT2-T4aN0/1M0 or cT1N1M0) ineligible for or refused cisplatin and were planned for RC

📌 EFS
D+EV vs control: NR vs 12.1 HR 0.51
D+T+EV: NR (HR 0.61)

📌 OS
D+EV vs control: 78 VS 69% at 24m HR 0.58
Triplet vs control: NS

📌 pCR Doublet vs control: 45 vs 8%

🩸ctDNA clearance impacts survival

@OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @brunolarvol
👇🏽👇🏽